Edition:
India

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

17.95USD
19 Jan 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$17.95
Open
$17.95
Day's High
$18.00
Day's Low
$17.95
Volume
851,573
Avg. Vol
321,349
52-wk High
$18.75
52-wk Low
$9.30

Latest Key Developments (Source: Significant Developments)

Sucampo Pharmaceuticals Received Notification From FDA That It Has Extended PDUFA Goal Date By 3 Months
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Sucampo Pharmaceuticals Inc ::SUCAMPO PHARMACEUTICALS - ON DEC 28, RECEIVED NOTIFICATION FROM U.S. FDA THAT IT HAS EXTENDED PDUFA GOAL DATE BY 3 MONTHS FOR SNDA FOR LUBIPROSTONE.SUCAMPO PHARMACEUTICALS - EXTENDED USER FEE GOAL DATE FOR THE SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR LUBIPROSTONE IS APRIL 28, 2018- SEC FILING.  Full Article

Sucampo Pharma Says If Merger Agreement Terminated, Co Agreed To Pay Mallinckrodt Fee Of $44 Million
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Sucampo Pharmaceuticals Inc ::SUCAMPO PHARMACEUTICALS SAYS IF MERGER AGREEMENT TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO AGREED TO PAY MALLINCKRODT FEE OF $44 MILLION - SEC FILING.  Full Article

Mallinckrodt To Buy Sucampo Pharmaceuticals For About $1.2 Bln
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT TO ACQUIRE SUCAMPO PHARMACEUTICALS FOR APPROXIMATELY $1.2 BILLION.MALLINCKRODT - ‍TRANSACTION WAS APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​ .MALLINCKRODT PLC - MALLINCKRODT TO COMMENCE CASH TENDER OFFER FOR $18.00 PER SHARE, WITH SUPPORT FROM KEY SUCAMPO SHAREHOLDERS.MALLINCKRODT SAYS EXPECTS ACCRETION TO 2018 ADJUSTED DILUTED EARNINGS PER SHARE OF AT LEAST $0.30 AS RESULTS OF DEAL.MALLINCKRODT - DEAL EXPECTED TO BE FUNDED THROUGH BORROWINGS UNDER CO'S EXISTING REVOLVING CREDIT FACILITY, NEW SECURED TERM LOAN FACILITY, CASH ON HAND.MALLINCKRODT PLC - FOLLOWING DEAL, CO INTENDS TO UTILIZE "SIGNIFICANT" CASH GENERATION TO FOCUS ON REDUCING OUTSTANDING DEBT OVER TIME.MALLINCKRODT SAYS EXPECTS ACCRETION TO 2018 ADJUSTED DILUTED EPS OF AT LEAST $0.30; AT LEAST DOUBLE THAT IN 2019, ASSUMING DEAL CLOSES IN Q1 2018.  Full Article

Linden Capital Reports A 5.1 Pct Passive Stake In Sucampo Pharmaceuticals
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Sucampo Pharmaceuticals Inc ::LINDEN CAPITAL L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DECEMBER 6, 2017 - SEC FILING.  Full Article

Sucampo reports Q3 GAAP earnings per share $0.19
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Sucampo Pharmaceuticals Inc :Sucampo reports third quarter 2017 financial results.Q3 GAAP earnings per share $0.19.Q3 revenue $61.3 million versus I/B/E/S view $58 million.Q3 earnings per share view $0.25 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $1.10 to $1.15.Q3 adjusted earnings per share $0.27.Sucampo Pharmaceuticals Inc - For FY17 ‍sucampo now expects total revenue of $250.0 million to $255.0 million​.Q3 earnings per share view $0.25, revenue view $58.0 million -- Thomson Reuters I/B/E/S.Sucampo Pharmaceuticals Inc - Sees FY 2017 ‍free cash flow of $99.0 million to $104.0 million​.Sucampo Pharmaceuticals - ‍Increases 2017 guidance for all key financial metrics based on "stronger than expected" sales of Amitiza in U.S. & Japan.FY2017 earnings per share view $1.01, revenue view $234.5 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo reports Q2 GAAP loss per share $0.02
Wednesday, 3 Aug 2016 

Sucampo Pharmaceuticals Inc : Q2 GAAP loss per share $0.02 . Q2 adjusted earnings per share $0.23 . Q2 earnings per share view $0.22 -- Thomson Reuters I/B/E/S . Q2 revenue $52 million versus I/B/E/S view $48.6 million . Sees FY 2016 adjusted earnings per share $0.97 to $1.07 . Sees FY 2016 revenue $195 million to $205 million .FY2016 earnings per share view $1.01, revenue view $203.6 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo Pharmaceuticals Inc reports top-line data from phase 2a study of cobiprostone
Tuesday, 19 Apr 2016 

Sucampo Pharmaceuticals Inc:Reports top-line data from phase 2a study of cobiprostone in patients with PPI-refractory non-erosive reflux disease and symptomatic gastroesophageal reflux disease.Says trial did not meet its primary endpoints.Says intends to discontinue development of cobiprostone for PPI-refractory NERD/sGERD.  Full Article

Sucampo Pharmaceuticals Inc reiterates FY 2016 guidance
Tuesday, 8 Mar 2016 

Sucampo Pharmaceuticals Inc:Reiterated its earnings guidance for FY 2016.Expects total revenue of $195.0 million to $205.0 million, adjusted net income of $45.0 million to $50.0 million, adjusted EPS of $0.97 to $1.07, and adjusted EBITDA of $100.0 million to $105.0 million.Says adjusted net income guidance excludes amortization of acquired intangibles of about $17.6 million and amortization of the remaining inventory step-up costs of about $8.9 million.  Full Article

BRIEF-Sucampo Pharmaceuticals Received Notification From FDA That It Has Extended PDUFA Goal Date By 3 Months

* SUCAMPO PHARMACEUTICALS - ON DEC 28, RECEIVED NOTIFICATION FROM U.S. FDA THAT IT HAS EXTENDED PDUFA GOAL DATE BY 3 MONTHS FOR SNDA FOR LUBIPROSTONE